International Vaccine Institute And FII Institute Sign Mou To Cooperate On Scientific Research And Publication

Published
May 19, 2021

INTERNATIONAL VACCINE INSTITUTE AND FII INSTITUTE SIGN MOU TO COOPERATE ON SCIENTIFIC RESEARCH AND PUBLICATION The agreement is an effort to further scientific research in infectious diseases and make knowledge more accessible through advocacy and joint publications.

Riyadh and Seoul, May 19th, 2021 – The International Vaccine Institute (IVI) and the Future Investment Initiative Institute (FII-I) signed a memorandum of understanding (MOU) to increase awareness and muster support to tackle infectious diseases. IVI and FII-I will endeavor to pursue strategic collaborations with each other, working together on topics that create value for both organizations within Healthcare, more specifically within the field of Infectious Diseases.

• Dr. Jerome Kim, Director General of IVI, and Rakan Tarabzoni, Chief Operating Officer of the FII Institute, signed the agreement on March 24th from Seoul, South Korea and Riyadh, Saudi Arabia. This MOU will create further opportunities for IVI and FII Institute to continue developing and publishing content about vaccines and their role in strengthening global health.

• “IVI welcomes this new partnership with the FII Institute to mobilize support and advocacy for vaccines against highly problematic infectious diseases such as tuberculosis, exchange information and global health networks, and co-create research on the value of vaccines,’’ said Dr. Jerome Kim.

• “The agreement reflects the FII Institute’s eagerness to contribute at large scale to the global dialogue on healthcare. We look forward to a fruitful collaboration on tackling global health issues and raising awareness about potential solutions for them’’, said Richard Attias, CEO of the FII Institute.

IVI is a non-profit international organization dedicated to making available safe, effective, and affordable vaccines for the world’s “neglected” diseases. The FII Institute is an international non-profit organization, mandated to transform innovative research/projects into actionable solutions that tackle major societal issues.

ENDS

• About the International Vaccine Institute

The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). Headquartered in Seoul, South Korea, IVI was the first international organization hosted by Korea. The IVI Establishment Agreement has been signed by 36 signatory countries and the World Health Organization (WHO). Korea, Sweden, India, and Finland are IVI’s state funders.​The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). Headquartered in Seoul, South Korea, IVI was the first international organization hosted by Korea. The IVI Establishment Agreement has been signed by 36 signatory countries and the World Health Organization (WHO). Korea, Sweden, India, and Finland are IVI’s state funders.

Our mandate is to make vaccines available and accessible for the world’s most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, chikungunya, group A strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit https://www.ivi.int